Article - BioPharm International

ADVERTISEMENT

Article

Outsourcing Insights: Booming Biopharma Pipeline Straining CRO Capacity

May 1, 2007

Venture capital insiders say that the flow of funds into biopharma shouldcontinue, driven by the large amount of money available for investment.

Successful Steps for Outsourcing the Manufacture of Clinical Trials Materials

April 2, 2007

Consider the number of patients, the dose each will receive (and how this dose is calculated), the number of doses per patient, and what overage is needed to allow for vial breakage.

Outsourcing: What is the Path Forward?

April 2, 2007

The greatest benefits of outsourcing are realized when a company takes a strategic approach rather than a tactical approach.

The Importance of Project Management

April 2, 2007

Are the deadlines for your outsourced projects often not met? Are you unsure of the status of your project at any given time? Is the original budget of your study typically exceeded?

Analytical Testing to Support Biopharmaceutical Products

April 2, 2007

A tremendous amount of analytical testing is required to support a biopharmaceutical product from discovery, development, and clinical trials, through manufacturing and marketing. Numerous methods are used to fully characterize large molecules because of their complexity—characterizing them is significantly more difficult than it is for small molecules. Biopharmaceuticals are produced via living systems, i.e., E. coli, yeast, or mammalian cells, which require additional testing matrices.

Outsourcing Virtually Everything: Making the Semi-Virtual Model Work

April 2, 2007

Partnering with a surging number of CROs, CMOs, CSOs, and other niche providers, biopharm companies in 2007 will have an estimated spend of more than $7 billion on international clinical trial outsourcing alone.

Match.Contractmanufacturing: Finding The Perfect Match

April 2, 2007

The contract manufacturer must have sufficient capacity so it can absorb possible surge in demand, and back-up capability in case of a power failure or other event.

China Today: Vaccine Development in China

April 1, 2007

The Chinese vaccine market competition is now transferring from the former price-competition model to a technology- competition model.

Manufacturing: BioPharmaceutical Operations Roadmap 2007

April 1, 2007

Scale-up issues leading to long development times and deviations in the commercial facility is a critical challenge.

ADVERTISEMENT

ADVERTISEMENT

Click here